Compare SERV & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SERV | IVA |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 724.7M | 804.2M |
| IPO Year | N/A | 2020 |
| Metric | SERV | IVA |
|---|---|---|
| Price | $10.33 | $4.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $18.20 | $17.14 |
| AVG Volume (30 Days) | ★ 7.7M | 237.4K |
| Earning Date | 11-12-2025 | 09-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,944,483.00 | ★ $19,929,536.00 |
| Revenue This Year | $44.11 | N/A |
| Revenue Next Year | $891.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.76 | N/A |
| 52 Week Low | $4.66 | $2.11 |
| 52 Week High | $24.35 | $7.98 |
| Indicator | SERV | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 56.56 |
| Support Level | $9.77 | $4.12 |
| Resistance Level | $11.22 | $4.58 |
| Average True Range (ATR) | 0.80 | 0.20 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 20.19 | 85.83 |
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.